Eating disorders — including anorexia nervosa, bulimia nervosa, and binge-eating disorder — affect an estimated 9% of the global population across a lifetime, with some of the highest mortality rates of any psychiatric condition. Standard treatments including psychotherapy and medication leave a substantial number of patients without lasting recovery. Ibogaine, a psychoactive alkaloid derived from the Tabernanthe iboga plant, is being explored in early research for its potential to disrupt compulsive behavioral patterns and address underlying trauma — factors central to many eating disorders.

⚠️ Ibogaine carries serious cardiac risks and has caused fatalities. Medical supervision required. Do not self-administer.

What the Research Shows

Direct clinical research on ibogaine specifically for eating disorders remains extremely limited. No randomized controlled trials or large observational studies have been published targeting anorexia nervosa, bulimia nervosa, or binge-eating disorder as a primary endpoint. What exists at this stage consists of case reports, anecdotal accounts, and mechanistic hypotheses drawing on ibogaine's broader psychopharmacological profile.

The rationale for investigating ibogaine in eating disorders is largely borrowed from adjacent research areas. Eating disorders share neurobiological features with substance use disorders — including dysregulation of dopaminergic reward circuits, compulsive behavioral loops, and high rates of comorbid trauma and PTSD. Ibogaine has demonstrated meaningful effects in disrupting addictive patterns in opioid dependence studies, and researchers have proposed that similar mechanisms may be relevant to the compulsive restrictive or bingeing behaviors seen in eating disorder presentations.

The broader psychedelic research field offers some indirect context. Psilocybin has entered Phase 2 clinical trials for anorexia nervosa, with researchers at institutions including Johns Hopkins and Imperial College London reporting early signals of reduced food-related anxiety and increased psychological flexibility. These findings have helped open the door to investigating other psychedelic compounds — including ibogaine — in eating disorder populations, though ibogaine's distinct pharmacology, longer duration of action, and more complex safety profile mean it cannot be assumed to behave similarly.

Case reports from ibogaine treatment centers in Mexico, Canada, and Europe occasionally describe patients who sought treatment primarily for eating disorder behaviors, or who reported meaningful shifts in their relationship with food, body image, and control following ibogaine sessions. However, these accounts are not systematically collected, are subject to reporting bias, and do not constitute clinical evidence.

Researchers have also noted ibogaine's interaction with sigma-2 receptors and its downstream effects on neuroplasticity — including upregulation of brain-derived neurotrophic factor (BDNF) — as a potentially relevant mechanism for eating disorders, given that rigid cognitive patterns and impaired neuroplasticity are increasingly recognized as features of particularly treatment-resistant anorexia nervosa.

Clinical Trial Results

No completed clinical trials have evaluated ibogaine specifically as a treatment for eating disorders. The table below reflects the current state of evidence across ibogaine's most studied indications, for context:

Trial Phase N Key Outcome Year
Alper KR et al. — Opioid dependence case series Case series 33 25 of 33 completed detox without withdrawal medications 1999
Mash DC et al. — Opioid & cocaine dependence (St. Kitts) Open-label 191 Reductions in drug use and craving; no serious adverse events in study cohort 2018
Noller GE et al. — Opioid dependence (New Zealand) Prospective observational pilot 14 Significant reduction in ASI-Lite drug use scores at 12-month follow-up; one patient death during treatment 2018
Brown TK & Alper K — Opioid dependence Observational 30 50% reported no opioid use at 1-month follow-up 2018
Ibogaine for eating disorders — — No completed clinical trials as of 2026 —

How Ibogaine May Help

While speculative at this stage, several mechanistic pathways have been proposed to explain why ibogaine could be relevant to eating disorder treatment:

Disruption of Compulsive Behavioral Circuits

Eating disorders — particularly anorexia and bulimia — involve deeply entrenched compulsive loops: restricting, bingeing, purging, and ritualistic behaviors around food that can persist even when the individual consciously wants to stop. Ibogaine is thought to act as a "circuit breaker" for compulsive patterns by resetting activity in the nucleus accumbens and modulating dopamine signaling in reward pathways. This mechanism has been most studied in opioid and stimulant dependence, but the shared neurobiological architecture of compulsive behavior disorders makes it a reasonable area of investigation.

Trauma Processing and Psychological Flexibility

Research consistently shows that eating disorders — especially anorexia and binge-eating disorder — carry high rates of comorbid trauma, childhood adversity, and PTSD. Ibogaine's visionary and introspective properties at full psychedelic doses are reported by many patients to facilitate profound autobiographical review and emotional processing of past trauma. If confirmed in structured clinical settings, this could address one of the most difficult-to-treat dimensions of eating disorder pathology.

Neuroplasticity Enhancement

Preclinical research suggests ibogaine may increase BDNF expression in key brain regions. Anorexia nervosa in particular has been associated with reduced cognitive flexibility and neural rigidity — and BDNF has been investigated as a potential biomarker and therapeutic target. Enhancing neuroplasticity could, in theory, help the brain form new patterns around eating, body perception, and self-worth, though this remains to be tested in human eating disorder trials.

Serotonin System Modulation

Ibogaine inhibits the serotonin transporter (SERT), increasing serotonergic tone — a mechanism shared with many current antidepressants and medications used in eating disorder treatment. Disrupted serotonin signaling plays a well-documented role in both anorexia and bulimia, and this pathway represents another plausible bridge between ibogaine's pharmacology and eating disorder biology.

Reduction in Ego Rigidity

A hallmark of severe anorexia is a rigid, ego-syntonic relationship with the illness — patients frequently do not experience their disorder as foreign to their identity, making engagement with treatment deeply difficult. Psychedelic experiences, including those produced by ibogaine, are often described as temporarily dissolving rigid self-concepts. Some researchers and clinicians hypothesize that this could create therapeutic windows of openness, though this remains anecdotal and untested in controlled eating disorder research.

Limitations and What We Don't Know Yet

The honest picture is that ibogaine for eating disorders is in an extremely early, exploratory stage with significant unknowns:

  • No dedicated clinical trials exist. Every mechanism discussed above is theoretical or borrowed from other conditions. There is no clinical trial evidence that ibogaine is safe or effective for anorexia, bulimia, or binge-eating disorder.
  • Medical vulnerability in eating disorder patients is a serious concern. Individuals with active eating disorders — particularly anorexia nervosa — are often medically compromised: low body weight, electrolyte imbalances, bradycardia, and prolonged QT intervals are common. These factors significantly amplify ibogaine's already serious cardiac risks, and no safety data exists for this population.
  • No validated outcome measures have been applied. We do not know how to measure ibogaine's impact on eating disorder-specific symptoms such as EDE-Q scores, weight restoration, or binge-purge frequency in a research context.
  • Psychedelic experiences can be destabilizing. For individuals with eating disorders, who often have fragile self-esteem, trauma histories, and complex body image disturbances, an intense dissociative experience like ibogaine's could potentially be retraumatizing rather than healing — a risk that has not been studied.
  • Publication bias in anecdotal reports. The case reports and center experiences that exist in the public domain are far more likely to represent positive outcomes. Adverse outcomes and non-responses are almost certainly underreported.
  • Interaction with existing medications. Many eating disorder patients are taking SSRIs, antipsychotics, or other medications with serotonergic or QT-prolonging effects. Ibogaine's interactions with these medications in this population are not well characterized.

Safety Considerations

For individuals with eating disorders, ibogaine's safety profile raises concerns that go beyond its general risks:

Cardiac Risk Amplified by Malnutrition

Ibogaine prolongs the QT interval and has been associated with fatal cardiac arrhythmias, most commonly in contexts of inadequate screening. In patients with anorexia nervosa, electrolyte abnormalities — particularly hypokalemia and hypomagnesemia from malnutrition or purging — independently prolong the QT interval and increase arrhythmia risk. The combination of ibogaine and a metabolically compromised cardiac substrate represents a potentially high-risk scenario that has not been formally studied. Magnesium co-administration has been used in some clinical ibogaine protocols (as in the Stanford/VETS veterans study) to help mitigate QT prolongation, but its adequacy in malnourished patients is unknown.

Electrolyte Instability

Purging behaviors in bulimia nervosa cause hypokalemia, hyponatremia, and hypochloremia — all of which can contribute to dangerous cardiac rhythms. Any ibogaine protocol would require thorough electrolyte correction prior to administration, but resumption of purging behavior could rapidly destabilize a patient between screening and treatment.

Psychological Vulnerability

Ibogaine typically produces an intense, multi-hour visionary and introspective experience. For individuals with severe body dysmorphia, trauma histories, or fragile psychological stability — common in eating disorder presentations — this experience could be overwhelming or destabilizing. Adequate psychological screening and robust therapeutic support would be essential.

Duration and Physical Demands

An ibogaine session typically lasts 12–24 hours or longer, during which patients must remain relatively still. For medically frail patients with low body weight, this prolonged period without adequate nutrition and hydration poses additional physiological risks.

⚠️ People with active eating disorders — particularly anorexia nervosa — are at elevated baseline cardiac risk due to electrolyte abnormalities and malnutrition. Ibogaine's QT-prolonging effects may be significantly more dangerous in this population. No safety data exists. Medical supervision and thorough pre-treatment medical clearance are essential.

Current Treatment Landscape

Understanding where ibogaine might eventually fit — if evidence develops — requires knowing what currently exists for eating disorders:

Anorexia nervosa has no FDA-approved pharmacological treatment. Olanzapine has some evidence for weight gain support, and psychotherapies including Family-Based Treatment (FBT) for adolescents and Cognitive Behavioral Therapy Enhanced (CBT-E) for adults are considered first-line. However, long-term remission rates remain discouraging — a substantial proportion of patients with severe, enduring anorexia do not achieve lasting recovery with current approaches.

Bulimia nervosa has one FDA-approved medication (fluoxetine at 60mg/day) and strong evidence for CBT. Outcomes are meaningfully better than anorexia, but relapse remains common.

Binge-eating disorder has FDA-approved pharmacotherapy (lisdexamfetamine/Vyvanse) as well as evidence for CBT and interpersonal therapy.

The broader psychedelic research space is more active: psilocybin is currently in Phase 2 trials for anorexia, with early results suggesting improvements in psychological flexibility and quality of life. MDMA-assisted therapy, which has a strong trauma-processing rationale, is also being considered for eating disorder research given high PTSD comorbidity. Ibogaine is further behind in this specific application, but its unique pharmacological profile — particularly its long duration, dissociative qualities, and effects on reward circuitry — makes it a scientifically plausible candidate for future investigation, provided that the substantial safety challenges for this medically vulnerable population can be adequately addressed.

Currently, individuals seeking ibogaine for eating disorders would access treatment only through unregulated international clinics, primarily in Mexico, where ibogaine is legal. This context carries substantial risks: variable medical screening, inconsistent cardiac monitoring, and no standardized protocols for eating disorder-specific vulnerabilities.

Frequently Asked Questions

No. As of 2026, no completed clinical trials have evaluated ibogaine specifically for anorexia nervosa, bulimia nervosa, or binge-eating disorder. The available evidence consists of case reports, anecdotal accounts from treatment centers, and mechanistic hypotheses drawn from ibogaine's effects in other conditions. Any claims of proven efficacy for eating disorders are not supported by current clinical data.
Several factors drive interest. Eating disorders — especially severe anorexia — are notoriously difficult to treat, and many patients exhaust conventional options without lasting recovery. Ibogaine's proposed ability to disrupt compulsive behavioral patterns, facilitate trauma processing, and promote neuroplasticity aligns conceptually with the challenges eating disorders present. The broader interest in psychedelic therapies for eating disorders (including psilocybin research) has also increased awareness of ibogaine as a potential avenue. However, interest and plausible mechanisms are not substitutes for clinical evidence.
Likely yes, for several reasons. Ibogaine prolongs the cardiac QT interval and has been associated with fatal arrhythmias. People with eating disorders — particularly those with active anorexia or bulimia involving purging — frequently have electrolyte abnormalities (low potassium, magnesium) and cardiac changes that independently increase arrhythmia risk. The combination may be significantly more hazardous than in a healthy individual. No safety studies have been conducted in this population, meaning the true risk level is unknown. This is a critical gap that would need to be addressed before any responsible clinical research could proceed.
Eating disorders share neurobiological features with compulsive and addictive behaviors, including dysregulation of dopamine reward circuits and serotonin signaling — both systems ibogaine is known to affect. Ibogaine also inhibits the serotonin transporter (as SSRIs do) and has been shown in preclinical research to upregulate BDNF, a protein involved in neuroplasticity that may be relevant to the cognitive rigidity seen in anorexia. Additionally, the intense introspective experience ibogaine produces may help patients process underlying trauma. These are mechanistic hypotheses, not proven therapeutic effects in eating disorder populations.
No registered clinical trials specifically investigating ibogaine for eating disorders were identified as of 2026. The psychedelic eating disorder research space is currently more active around psilocybin, which has reached Phase 2 trials for anorexia nervosa at multiple institutions. Ibogaine research has focused primarily on opioid use disorder and, more recently, PTSD in veterans. Future trials targeting eating disorders would require extensive safety work given the medical vulnerability of this population before proceeding to efficacy investigations.
Several things are critical to understand: There is no clinical evidence that ibogaine is effective for eating disorders. The cardiac risks of ibogaine are likely amplified by the electrolyte abnormalities and cardiac vulnerability common in eating disorders. Ibogaine is a Schedule I controlled substance in the United States with no approved medical use. Treatment is currently available only through unregulated international clinics. Anyone considering ibogaine should be honest with providers about their full medical history — including their eating disorder — and obtain comprehensive cardiac screening including ECG and electrolyte panels. Consulting with a physician knowledgeable about both eating disorders and psychedelic medicine is strongly advisable.
Psilocybin is considerably further ahead in eating disorder research. Phase 2 clinical trials for anorexia nervosa have been conducted at Johns Hopkins and Imperial College London, with early signals suggesting improvements in psychological flexibility, quality of life, and reduced food-related anxiety. Psilocybin also has a more favorable safety profile than ibogaine — it does not carry the same cardiac risks and has a shorter, more predictable duration of action. Ibogaine's more complex pharmacology and greater medical risk profile mean it would require substantially more safety groundwork before comparable eating disorder trials could responsibly proceed.

Informational only. Not medical advice. Ibogaine is Schedule I in the US. Consult qualified professionals before considering treatment.